Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.

Researchers behind a new study say that the methods used to evaluate AI systems’ capabilities routinely oversell AI performance and lack scientific rigor. The study, led by researchers at the Oxford ...

Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for cancer patients. Enoby targets bone loss in patients on hormone-based ...

Consumers continued to flock to Costco (NASDAQ:COST), taking advantage of the warehouse store’s sizable bulk-rate savings fourth quarter results beating Wall Street’s expectations on nearly every ...

The iPhone 17 and iPhone 17 Pro both received facelifts for 2025. Here's how the specs of the two compare, and whether it is worth paying at least $300 more to go Pro. Each year, Apple brings out its ...

BANGKOK, July 24 (Reuters) - Months of simmering tensions between Cambodia and Thailand exploded into armed conflict on Thursday, including the deployment of a Thai F-16 fighter jet, in the heaviest ...

OpenAI is building new features within ChatGPT that would make it a direct competitor with workplace productivity suites like Google Workplace and Microsoft Office 365, The Information reported ...

Congressional Republicans approved President Donald Trump’s sweeping tax and spending cuts package, otherwise known as the “big, beautiful bill.” The House GOP ultimately passed the Senate’s ...

Pew Research Center conducted this study to continue tracking news consumption and trust across a wide range of specific news sources. We last published similar reports in 2020 (based on a 2019 survey ...